雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis. Yasuda Shinsuke 1 1Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan. pp.668-676
Published Date 2018/4/28
DOI https://doi.org/10.20837/4201805668
  • Abstract
  • Look Inside
  • Reference

 CTLA4 abolishes interaction between CD28 on T cells and B7 molecules on antigen presenting cells. CTLA4-Ig, abatacept(ABT)was developed as a drug with multipotent inhibitor against activated T/B cells, monocytes, dendritic cells, macrophages and osteoclast progenitors expressing B7 molecules. In phase Ⅲ RCTs, clinical effects of ABT have been established in MTX-naïve, MTX-IR and TNF inhibitor-IR patients with RA. Moreover, in head-to head comparison with representative TNF inhibitors, ABT exerted compatible clinical effect. In clinical practice, ABT is recognized as a biological DMARD with good safety profile. Reduction or withdrawal of ABT is also proposed in patients who achieved remission under treatment with ABT+MTX. In conclusion, ABT can be included in the treatment strategy of RA with wide clinical variance.



基本情報

電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有